Grown Rogue International (GRUSF) Capital Expenditures Growth (1y) (2019 - 2026)
Grown Rogue International (GRUSF) Capital Expenditures Growth (1y) (2019 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Capex Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 88.58 Bn | 86.72 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 35.90 Bn | 32.16 Bn | 1.97 Bn | 32.28% |
| 3 | Zoetis | 32.33 Bn | 30.39 Bn | 1.62 Bn | -38.20% |
| 4 | Takeda Pharmaceutical | 27.49 Bn | 23.43 Bn | 4.39 Bn | -15.72% |
| 5 | United Therapeutics | 23.14 Bn | 20.99 Bn | 648.10 Mn | 32.98% |
| 6 | RedHill Biopharma | 20.53 Bn | 20.53 Bn | - | - |
| 7 | Viatris | 20.29 Bn | 18.49 Bn | 1.16 Bn | -6.34% |
| 8 | Neurocrine Biosciences | 17.93 Bn | 16.62 Bn | 800.70 Mn | -86.92% |
| 9 | Elanco Animal Health | 12.63 Bn | 12.21 Bn | 785.00 Mn | -21.54% |
| 10 | Grown Rogue International | 94.97 Mn | 81.27 Mn | 3.96 Mn | 942.27% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 942.27% |
| Dec 31, 2025 | -16.65% |
| Sep 30, 2025 | 16.65% |
| Jun 30, 2025 | -235.68% |
| Mar 31, 2025 | 181.24% |
| Dec 31, 2024 | 1,000,503,556.29% |
| Jan 31, 2023 | 93.67% |
| Jan 31, 2022 | -261.34% |
| Oct 31, 2021 | -1,283.88% |
| Jul 31, 2021 | -211.96% |
| Apr 30, 2021 | -45.03% |
| Jan 31, 2021 | -3,611.84% |
| Oct 31, 2020 | -90.74% |
| Jul 31, 2020 | 2,176.22% |
| Apr 30, 2020 | -143.90% |
| Jan 31, 2020 | 105.73% |
| Oct 31, 2019 | -74.34% |
| Jul 31, 2019 | -134.51% |
| Apr 30, 2019 | 12.30% |
| Jan 31, 2019 | 89.02% |